title: Salvage therapy with endostatin, low-dose homoharringtonine, and cytarabine in combination with granulocyte-colony stimulating factor for elderly patients with primary refractory acute myeloid leukemia.
authors.affiliation: Henan Key Laboratory of Experimental Hematology, Henan Institute of Hematology, Henan Tumor Hospital, Zhengzhou University, China.
authors.forename: Baijun
authors.initials: B
authors.lastname: Fang
authors.forename: Yuzhang
authors.initials: Y
authors.lastname: Liu
authors.forename: Jian
authors.initials: J
authors.lastname: Zhou
authors.forename: Yanan
authors.initials: Y
authors.lastname: Li
authors.forename: Yongping
authors.initials: Y
authors.lastname: Song
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage; D043169:Endostatins / Q000008:administration & dosage; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006248:Harringtonines / Q000008:administration & dosage; D000077863:Homoharringtonine; D006801:Humans; D053208:Kaplan-Meier Estimate; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D011379:Prognosis; D016879:Salvage Therapy; D016896:Treatment Outcome
chemical_list: D043169:Endostatins; D006248:Harringtonines; D003561:Cytarabine; D016179:Granulocyte Colony-Stimulating Factor; D000077863:Homoharringtonine